Manitoba pharmacists will soon have ability to prescribe birth control, HIV medications
Health Minister Uzoma Asagwara told the legislature Wednesday that granting pharmacists the means to assess and prescribe contraceptives is a "very reasonable expansion of scope for pharmacists in Manitoba."
The minister added in an interview the government is moving "very quickly" on the changes, which will take effect "in the coming days and weeks."
"We're trying to get it out the door as quickly as we can for pharmacists across the province who have been asking for this for years," they said.
Pharmacists will also be able to prescribe HIV medications beginning this summer, a government official said.
Manitoba, Ontario and the three territories are the only places in Canada that do not currently allow pharmacists to prescribe birth control.
Emergency contraceptives, such as the Plan B pill, are currently available without a prescription from pharmacies.
"Right now in Manitoba, pharmacists do not have the ability to practise at their full scope, the way that they should," said Asagwara, who pledged "to go even further" in granting pharmacists more prescribing authority.
Members of the industry association Pharmacists Manitoba were in the legislature to watch question period Wednesday, after they were informed that Liberal MLA Cindy Lamoureux would ask questions about pharmacists' scope of practice.
In her first question, Lamoureux asked if the government planned to "enable and empower pharmacists who directly assess and prescribe contraception."
The question prompted a sometimes rare occurrence in question period: a direct answer to the question posed.
"The short answer to that question, for the member of Tyndall Park, is yes," Asagwara said.
Britt Kural, the pharmacy practice adviser with Pharmacists Manitoba, said she was "pleasantly surprised" by the response.
"We had no idea that there was going to be something right around the corner," said Kural.
The pharmacist said she believes she and her colleagues will be able to prescribe products like daily oral birth control pills, hormonal injections and IUDs, but the province hasn't provided those details yet.
Currently, a patient must go to a doctor's office or a nurse practitioner to receive a prescription for birth control, and must then visit a pharmacist to pick it up.
This regulatory change will save patients from seeing a doctor or nurse practitioner.
"Quite often pharmacists are a first point of care for many people in Manitoba, because they don't have access to a primary care physician or a nurse practitioner, especially in rural and remote communities," Kural said.
She couldn't estimate what kind of uptake pharmacists will see, but said her profession is eager to help.
Women's Health Clinic executive director Kemlin Nembhard said any step toward making prescription birth control more accessible is worth celebrating.
The change will make contraceptives easier to access for people without a family doctor, or for young people who worry about their parents finding out, she said.
While Manitoba's NDP government has been offering free prescription birth control since October of last year, Nembhard said some hurdles to accessing these contraceptives persist, such as the requirement to have a health card. It's one of the reasons the clinic runs a free birth control program, funded entirely through donations.
"It would be great for us to get funding through the province to support that program," Nembhard said.
Kural said Manitoba's pharmacists would like to further expand their prescribing authority. Some options could include prescriptions to treat the minor ailments pharmacists are already assessing, such as strep throat, ear infections and cold sores, Kural said.
Any such move would require regulatory changes from the province.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
WebMD
3 hours ago
- WebMD
Breakthroughs in HIV
It's been over 40 years since the emergence of HIV. It's killed hundreds of thousands of Americans, and millions of people globally. Those numbers would be even higher without medical breakthroughs. Let's talk about some of them. In 1996, Highly Active Antiretroviral Therapy (HAART) was developed. It suppresses the virus from replicating and attacking your immune system, which lowers your viral load and increases the CD4 (white blood cells that fight infections for your immune system). That reduces your risk of opportunistic infections and extends your life expectancy. The decrease in viral load makes HIV less transmissible and helps reconstitute your immune system, but it took a while before it was known by how much This was a major breakthrough in HIV treatment and prevention. But it was hardly the first. Perhaps the first big break came in 1983, when scientists isolated the virus that pinpointed the cause of AIDS. This revolutionized the understanding of AIDS — where it was, how it works, and how to combat it. Then in 1985, the first HIV blood test was licensed. This was a breakthrough of sorts, because it allowed the virus to be detected before it was too late. But there was still no treatment. That came in 1987 when AZT was developed. AZT was the first antiretroviral treatment for HIV-AIDS. It helped and prevented mother-to-child transmission of the virus. But it had serious side effects. I've heard horrible stories from AZT survivors, but it was all that was available at the 1996, when HAART changed everything. By 1997, it was the standard of care for new HIV cases. In 2012, it was discovered that providing HIV medication to HIV-negative people at high risk for the virus could prevent transmission, with an incredible success rate. This is called pre-exposure prophylaxis or PrEP. It was meant to be another amazing breakthrough in science. For the first time, there was a proven method of preventing HIV transmission. The implications included ending transmission of HIV, and ending the HIV-AIDS epidemic. But PrEP hasn't been widely accepted by the public, mostly due to stigma associated with HIV and LGBTQ people. So we're yet to achieve those goals. The year 2016 changed my life more than any other. I was at a conference in Florida where Bruce Richman spoke about U=U. It played a huge role in my decision to become an HIV advocate. I've been an ambassador for U=U ever since. What is U=U? Undetectable equals Untransmittable means that when you take HIV medication as prescribed, you can achieve an undetectable viral load. This means there's not enough virus in your blood to be counted. What happens to the virus? Small amounts of it can survive but remain harmlessly dormant in your body, in small amounts known as reservoirs. The virus can't be transmitted sexually or mother to child. People who live with HIV can safely have children with no risk of transmission to their partner or baby. This revelation was monumental and it's changed lives. It was a breakthrough in understanding. In 2021, there came the first long-acting injectable. It was a breakthrough for those who struggled with pill fatigue or forgetfulness. Pill fatigue is a common problem, especially because there's also stigma associated with simply taking meds for HIV. I remember learning about injectable HIV medication at a conference called CROI (Conference on Retroviruses and Opportunistic Infections). It's a scientific event that attracts leading experts who discuss research and findings for collective understanding. I've attended the conference twice as a community liaison and learned so much about HIV research and the experts doing it. I learned about the potential for longer acting treatments, and about research exploring different methods of delivery, from injectable treatments to the possibility of implants. I can tell you that even a few years ago, research for a cure of HIV-AIDS was getting really exciting. I truly believe we're close to finding a cure. Now is not the time to kill funding dedicated to this research. I've talked about a lot of breakthroughs in HIV. This year, that list of breakthroughs adds another big advancement. In 2025 the FDA approved a drug that can be injected twice yearly, once every 6 months. It can also be used as PrEP, which has also been approved. That's incredible! You don't have to remember to take meds every day, carry meds with you, or be seen taking them. I hold on to hope that one day one of these breakthroughs will change public perception of HIV. There's no reason to fear this virus as long as you have access to the medicine. The stigma of HIV is antiquated. It's based on a mysterious disease that was a certain death sentence and only affects gay men But none of this is true anymore. HIV is no longer the deadly disease it once was. With incredible advancements, there's no excuse for fear or stigma to exist. HIV today is nothing more than a chronic condition that's easily managed, and only getting better with time. I believe we're close to a cure. I just learned that researchers have found a way to awaken dormant HIV cells. I find that extremely exciting and wonder if it could lead to a cure. If dormant cells can be awakened, then targeted and killed, that could be a cure. It's so exciting that we're getting closer, so it's no time for defunding HIV research and prevention efforts.
Yahoo
3 hours ago
- Yahoo
Why a tropical paradise has the world's fastest growing HIV epidemic
The jump in cases can only be described as 'explosive', said Dr Kesa Tuidraki. In hospitals and clinics across Fiji, doctors used to diagnosing a trickle of HIV infections are now confronting a flood. Just three years ago the archipelago reported 245 new cases. But by 2024, the government said that figure had jumped 550 per cent to 1,583, earning Fiji a grim new title: after decades of minimal spread, the tropical paradise now has the world's fastest growing HIV epidemic. 'By the time we realised what was happening, boom, the explosive numbers came in,' said Dr Tuidraki, acting country director at Medical Services Pacific (MSP), which runs sexual health clinics in Fiji. 'Honestly, I think we became complacent… now we're left racing to just catch up.' The sudden spiral is linked to a boom in methamphetamines. The archipelago, home to some 900,000 people across hundreds of islands, has for years been a transit point on the 'Pacific drug highway'. But since 2020 domestic consumption has surged, as the pandemic disrupted illicit trade routes. 'The big impact here was Covid,' said Eamonn Murphy, the Asia-Pacific region director of UNAIDS. 'Drug supply used to transit through Fiji, it wasn't really a domestic market. But during Covid, the drug trade got stuck there. That's when increasing use of injecting drugs met a background epidemic that had been neglected.' Experts have since reported children as young as 10 taking meth, while drug-related deaths – both from addiction and suspected gang activities – are rising. Meanwhile, HIV is being widely transmitted through needle sharing, chemsex and 'bluetoothing'. This third factor refers to a group of people pooling money to buy meth, before one person uses a syringe to inject the drug. Once they're high, another person draws their blood and injects themselves, chasing a secondary rush from the traces of meth in their bloodstream. 'We're gathering from patients that this is now common, and this is part of what's fuelling [the outbreak],' said Dr Tuidraki. 'But because of HIV's long incubation, we're only just seeing the rippling effects of Covid disruption now.' And the ripples are 'startling'. In the MSP clinic in the capital Suva, Dr Tuidraki has seen a steady flow of new HIV patients in the last 18 months – and unlike the past, many are very young. Too often, they seek care only when their condition is severe, and too often they drop off the radar and stop taking antiretroviral drugs. 'Trends have really changed from what we were seeing before,' Dr Tuidraki said. 'Patients are getting sicker more quickly – perhaps because of the mode of the transmission. The viral load is so high when people share drugs and needles. 'We're also seeing a much younger generation – before, most of the cases [were aged] 29 and above. But it's changed to the point that in our 10 to 19 year-olds, that's where we're having a lot of new cases.' Dr Tuidraki's observations are reflected in UNAIDS data published last month. Of new cases in 2024, 60 per cent of cases are among young people aged 10 to 29. Some 48 per cent were linked to injecting drug use – narrowly overtaking sexual transmission, the cause of 43 per cent of known infections, as the main source of spread. Meanwhile UNAIDS estimates that only a third of roughly 6,000 people living with HIV are aware of their status, pointing to widespread undetected transmission. What's more, just 24 per cent of those affected are currently receiving treatment; without the antivirals, they will almost certainly die. 'This shows there's a hell of a lot of work that needs to be done to get on top of the outbreak, and it needs a different response to the past,' Mr Murphy said. '[The country] never needed a drug-related response before… but if Fiji doesn't challenge community perceptions around drug use and how to respond to injecting drug use, this epidemic is going to blow up even more.' Shame and stigma Yet, even before the current wave of cases, stigma and stereotypes complicated both treatment and prevention efforts in the island nation. 'Fiji is a close knit, faith-based society where privacy is difficult and people fear being judged,' said Mark Shaheel Lal, who founded the awareness group Living Positive Fiji after testing positive for HIV. He's one of a small group of people living with the virus who have been willing to speak openly about their diagnosis and experience. 'It was a huge shock [to test positive]. But I had a few friends who had passed away from Aids, sadly, because they didn't begin treatment because of the stigma and shame and fear of going to the clinics to get the meds. 'So I felt I had a responsibility to actually come out and help other people living with HIV,' Mr Lal said. 'Conversations about same sex relationships, sex work and sexual health in general remains a taboo here – and this silence keeps HIV hidden, and makes prevention and support so much harder. If Fiji wants to reverse the trend, we must break the silence.' The government has taken some steps to tackle HIV – including designating the situation as a national outbreak in January. This allowed for the mobilisation of more resources, including $10 million Fijian (£3m) of new funding, the creation of a dedicated HIV unit in the ministry of health, expanded testing and an awareness campaign. Australia and New Zealand have also pledged support. But experts have called for drug harm reduction policies, including a needle exchange programme, and warned that a public health response to the meth crisis is needed alongside policing. They say Fiji should also expand sexual education in schools, ensure the wider availability of pre pre-exposure prophylaxis drugs, and introduce a peer counselling programme in clinics, to offer extra support to those who test positive. 'I'm supportive of the ministry [of health], but there's not been enough implementation yet – there's still a lot of talk,' said Dr Tuidraki. 'The outbreak was declared in January, it's now July. At the end of the day we're trying, but we're not moving with the speed the crisis requires.' She added that better training for health workers must also be prioritised within efforts to curb transmission, as too many have 'judgemental' mindsets and are 'not well informed on preventative measures'. 'This has been feedback from patients as one of the reasons they stop going in for treatment,' said Dr Tuidraki. 'HIV is too often associated with death, with something that's disgusting… I've been surprised that this is even true among healthcare workers.' Whether or not Fiji successfully tackles these challenges and reigns in HIV will have ramifications not just for the archipelago, but its neighbours across the region. 'Our big concern with Fiji is both the domestic epidemic, but it's also the gateway to the Pacific,' said Mr Murphy. 'Back in 2001, everyone was expecting an explosion in the Pacific because the background STI [sexually transmitted disease] rates were very high. 'It didn't happen then. But now, it's very much a reality looming.' Protect yourself and your family by learning more about Global Health Security Broaden your horizons with award-winning British journalism. Try The Telegraph free for 1 month with unlimited access to our award-winning website, exclusive app, money-saving offers and more.
Business Wire
4 hours ago
- Business Wire
Feinstein Institutes' Dr. Douglas F. Nixon Named Fellow of the Infectious Disease Society of America
BUSINESS WIRE)--For his contributions to immunovirology research, Douglas F. Nixon, MD, PhD, director of Northwell Health's Institute of Translational Research at the Feinstein Institutes for Medical Research, has been named a Fellow of the Infectious Diseases Society of America (IDSA). For over 30 years, Dr. Nixon has been a leading figure in immunovirology research, spanning clinical research, human immunology, basic virology and molecular biology. A pioneer in the study of human endogenous retroviruses (HERVs) – often called 'junk DNA' or 'dark genome' that does not code for genes – Dr. Nixon investigates their influence on neuroimmunological, neurodevelopmental and neurodegenerative conditions. As the leader of the Institute of Translational Research, Dr. Nixon heads a team whose research aims to accelerate the development of treatments for a variety of diseases, including Alzheimer's disease, cancer, HIV/AIDS, other viral infections and mental health disorders. 'I am honored to be elected a Fellow of the Infectious Diseases Society of America. This recognition is a testament to the collaborative spirit and dedication of my colleagues and mentors who have inspired and supported me throughout my career,' said Dr. Nixon. 'I am eager to contribute further to the critical mission of the society, advancing research and clinical care in infectious diseases for the benefit of patients worldwide.' Dr. Nixon has built a distinguished career in immunology and virology, earning degrees from University College London, the University of London, and the University of Oxford. His work spans biotech, academia and research institutions, including Rockefeller University, the Gladstone Institute, UCSF, George Washington University, Weill Cornell, and now at the Feinstein Institutes. With over 330 publications and continuous National Institutes of Health (NIH) funding for 25 years, Dr. Nixon's accomplishments include the Elizabeth Glaser Scientist Award, an NIH R37 merit award and fellowships in the American Society for Clinical Investigation, National Academy of Inventors and American Academy of Microbiology. He also led NIH initiatives focused on AIDS vaccine research and HIV cure research, which has earned him widespread recognition. 'Dr. Nixon's election as a Fellow of the Infectious Diseases Society of America is a high honor that reflects his exceptional scientific leadership,' said Kevin J. Tracey, MD, president and CEO of the Feinstein Institutes and Karches Family Distinguished Chair in Medical Research. 'His groundbreaking work in ancient DNA is transforming how we understand the origins and evolution of infectious diseases and is paving the way toward more effective treatments.' The IDSA is a global community of over 13,000 clinicians, scientists and public health experts who tackle infectious disease challenges ranging from microscopic microbes to widespread outbreaks. Driven by science, a commitment to health equity and a spirit of inquiry, IDSA members work to protect individual, community and global health by advancing the treatment and prevention of infectious diseases. Fellowship in IDSA is one of the highest honors in the field of infectious diseases, recognizing distinguished clinicians and scientists from the U.S. and around the world whose contributions continue to move the field forward. This year, the IDSA is welcoming 167 Fellows during its annual meeting in the fall. Dr. Nixon recently published research in Trends in Immunology that showed the five senses – sight, smell, taste, touch and sound – play a key role in the immune system. He calls this 'shared immunity,' and explains that the body can communicate and share immune benefits with others, even across generations. This research significantly expands the understanding of the complex interplay between the senses, the immune system and the environment though genetics and generational evolution, offering potential new directions for future research and the development of innovative therapeutic strategies to enhance immune defenses. About the Feinstein Institutes The Feinstein Institutes for Medical Research is the home of the research institutes of Northwell Health, the largest health care provider and private employer in New York State. Encompassing 50+ research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its six institutes of behavioral science, bioelectronic medicine, cancer, health system science, molecular medicine, and translational research. We are the global scientific leader in bioelectronic medicine – an innovative field of science that has the potential to revolutionize medicine. The Feinstein Institutes publishes two open-access, international peer-reviewed journals Molecular Medicine and Bioelectronic Medicine. Through the Elmezzi Graduate School of Molecular Medicine, we offer an accelerated PhD program. For more information about how we produce knowledge to cure disease, visit and follow us on LinkedIn.
